摘要:
A CCD 14 is disposed on the rear of the discharge cell structures 13, and light introduced from the discharge cell structures 13 to the rear side, or light leaked from the discharge cell structures 13 to the rear side is measured by the CCD 14. Then, the light amount measurement result outputted from the CCD 14 is quantified, and on the basis of this, the brightness correction is automatically performed.
摘要:
[Problem]To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases.[Means of solving the problem]A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR7—; and R1 to R7 are specific groups),a salt of the compound, or a solvate of the salt or the compound.
摘要:
[Problem]To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases.[Means of Solving the Problem]A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
摘要:
A burn-in prevention image signal is generated by subjecting an input image signal to blurring and then to contrast inversion to invert the contrast of the signal luminance level. The burn-in prevention image signal is used when the input image is a still image that does not change for a predetermined period.
摘要:
A stereoscopic display comprises: a first light-emitting unit that emits a first infrared ray in a first direction directed outward from a display surface; a second light-emitting unit that emits a second infrared ray in a second direction opposite the first direction; a display controller that alternately displays a right eye image and a left-eye image for a front-side user at a side of display surface in the first direction; and a vision controller that controls a vision of the user so that, in accordance with a control signal transmitted through the infrared ray, the image is visible
摘要:
There is disclosed an information display apparatus in which a control apparatus main body for controlling a plasma display apparatus for displaying video can disconnectably be connected to a substrate for outputting video data toward the control apparatus main body via a connector. The substrate includes: a RAM and ROM in which information is stored; a video control unit which uses the information to create the video data; and a CPU for controlling the RAM, ROM, and video control unit, the control apparatus main body includes a power source unit for supplying power to the substrate, and the power source unit is connected to the substrate via the connector.
摘要:
A touch panel apparatus includes a touch panel provided on a display; a touch-area detecting unit that detects a touch area when an object touches on a surface of the touch panel; and a determining unit that compares, when the touch-area detecting unit detects two touch areas, dimensions of the two touch areas, validates a touch area having a smaller dimension, and invalidates a touch area having a larger dimension.
摘要:
[Problem]To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like.[Means of solving the problem]A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; h is 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J1a is —CR11a—, N; J2 is —CR12aR12b—, —CR12c—; T is —CH2—, O, —S(O)i— (i is an integer of 0 to 2) or —NR7—; X is O, S, or —NR7—; ring A′″ is a benzene ring, a pyridine ring; ring B′ is a benzene ring, a pyridine ring, a pyrimidine ring; and R1 to R14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
摘要:
[Problem]To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like.[Means of solving the problem]A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; h is 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J1a is —CR11a—, N; J2 is —CR12aR12b—, —CR12c—; T is —CH2—, O, —S(O)i— (i is an integer of 0 to 2) or —NR7—; X is O, S, or —NR7—; ring A′″ is a benzene ring, a pyridine ring; ring B′ is a benzene ring, a pyridine ring, a pyrimidine ring; and R1 to R14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
摘要:
[Problem]To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases.[Means of solving the problem]A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.